VIM and neoplasm: The observed upregulation of vimentin in carboplatin and to a lesser extent paclitaxel resistant mesenchymal-like TNBC cells and a reduction in the expression of EpCAM in carboplatin and paclitaxel treated epithelial tumor cells is consistent with invasive tendencies for TNBC cells following treatment with chemotherapy agents (37).